Clinical presentation of Ixodes tick-borne borreliosis caused by Borrelia miyamotoi in the context of an immune response to the pathogen

Platonov, Alexander E.; Топоркова, М. Г.; Kolyasnikova, Nadezhda M.; Стуколова, О. А.; Dolgova, Anna; Brodovikova, A V; Makhneva, N A; Karan, Ludmila S.; Koetsveld, Joris; Shipulin, German A.; Maleev, V V

doi:10.17116/terarkh2017891135-43

Cited by 12 publications

(14 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, only ten of these patients were reactive in an immunoblot test commonly used in two-tier testing for Lyme disease (Table S1). These ten patients did not have erythema migrans or other Lyme borreliosis symptoms, but had a clinical presentation consistent with BMD with fever, thrombocytopenia and lymphopenia [1,22,23]. Since up to 40% of Ixodes ticks are infected with B. burgdorferi sl in the geographical location were these sera were collected, (asymptomatic) concurrent or previous B. burgdorferi sl could explain these positive blot results.…”

Section: Discussionmentioning

confidence: 91%

“…Stored sera were used from 46 patients with PCR-confirmed B. miyamotoi infection from two locations, Izhevsk (European Russia) and Yekaterinburg (Asian Russia) [1,22,23]. A total of 191 sera drawn at different time points were available from these 46 patients were tested by C6 Lyme enzyme immunoassay (EIA) (Immunetics, Oxford, UK) according to the manufacturer's instructions.…”

Section: C6 Eia and B Burgdorferi Western Blot In Pcr-proven Bmd Casesmentioning

confidence: 99%

See 1 more Smart Citation

Borrelia miyamotoi infection leads to cross-reactive antibodies to the C6 peptide in mice and men

Koetsveld¹,

Platonov

Kuleshov

et al. 2020

Clinical Microbiology and Infection

View full text Add to dashboard Cite

Objectives: Borrelia miyamotoi is a relapsing fever Borrelia, transmitted by hard (Ixodes) ticks, which are also the main vector for Borrelia burgdorferi. A widely used test for serodiagnosis of Lyme borreliosis is an enzyme immunoassay (EIA) based on the C6 peptide of the B. burgdorferi sl VlsE protein. We set out to study C6 reactivity upon infection with B. miyamotoi in a large well-characterized set of B. miyamotoi disease (BMD) patient sera and in experimental murine infection. Methods: We performed in silico analyses, comparing the C6-peptide to immunodominant B. miyamotoi variable large proteins (Vlps). Next, we determined C6 reactivity in sera from mice infected with B. miyamotoi and in a unique longitudinal set of 191 sera from 46 BMD patients. Results: In silico analyses revealed similarity of the C6 peptide to domains within B. miyamotoi Vlps. Cross-reactivity against the C6 peptide was confirmed in 21 out of 24 mice experimentally infected with B. miyamotoi. Moreover, 35 out of 46 BMD patients had a C6 EIA Lyme index higher than 1.1 (positive). Interestingly, 27 out of 37 patients with a C6 EIA Lyme index higher than 0.9 (equivocal) were negative when tested for specific B. burgdorferi sl antibodies using a commercially available immunoblot. Conclusions: We show that infection with B. miyamotoi leads to cross-reactive antibodies to the C6 peptide. Since BMD and Lyme borreliosis are found in the same geographical locations, caution should be used when relying solely on C6 reactivity testing. We propose that a positive C6 EIA with negative immunoblot, especially in patients with fever several weeks after a tick bite, warrants further testing for B. miyamotoi.

show abstract

Section: Discussionmentioning

confidence: 91%

Section: C6 Eia and B Burgdorferi Western Blot In Pcr-proven Bmd Casesmentioning

confidence: 99%

Borrelia miyamotoi infection leads to cross-reactive antibodies to the C6 peptide in mice and men

Koetsveld¹,

Platonov

Kuleshov

et al. 2020

Clinical Microbiology and Infection

View full text Add to dashboard Cite

show abstract

“…In that study, 46 cases of B. miyamotoi disease (BMD) were described with clinical manifestations that included fever and an influenza-like illness, with myalgia and arthralgia amongst other symptoms. Since then, several hundred BMD cases were identified in Russia [34,35]. BMD cases have been reported in Europe and the USA as well, but not with such frequency [2,[36][37][38][39].…”

Section: Introductionmentioning

confidence: 99%

Whole genome sequencing of Borrelia miyamotoi isolate Izh-4: reference for a complex bacterial genome

Kuleshov

Margos²,

Fingerle³

et al. 2020

BMC Genomics

View full text Add to dashboard Cite

Background: The genus Borrelia comprises spirochaetal bacteria maintained in natural transmission cycles by tick vectors and vertebrate reservoir hosts. The main groups are represented by a species complex including the causative agents of Lyme borreliosis and relapsing fever group Borrelia. Borrelia miyamotoi belongs to the relapsing fever group of spirochetes and forms distinct populations in North America, Asia, and Europe. As all Borrelia species B. miyamotoi possess an unusual and complex genome consisting of a linear chromosome and a number of linear and circular plasmids. The species is considered an emerging human pathogen and an increasing number of human cases are being described in the Northern hemisphere. The aim of this study was to produce a high quality reference genome that will facilitate future studies into genetic differences between different populations and the genome plasticity of B. miyamotoi. Results: We used multiple available sequencing methods, including Pacific Bioscience single-molecule real-time technology (SMRT) and Oxford Nanopore technology (ONT) supplemented with highly accurate Illumina sequences, to explore the suitability for whole genome assembly of the Russian B. miyamotoi isolate, Izh-4. Plasmids were typed according to their potential plasmid partitioning genes (PF32, 49, 50, 57/62). Comparing and combining results of both long-read (SMRT and ONT) and short-read methods (Illumina), we determined that the genome of the isolate Izh-4 consisted of one linear chromosome, 12 linear and two circular plasmids. Whilst the majority of plasmids had corresponding contigs in the Asian B. miyamotoi isolate FR64b, there were only four that matched plasmids of the North American isolate CT13-2396, indicating differences between B. miyamotoi populations. Several plasmids, e.g. lp41, lp29, lp23, and lp24, were found to carry variable major proteins. Amongst those were variable large proteins (Vlp) subtype Vlp-α, Vlp-γ, Vlp-δ and also Vlp-β. Phylogenetic analysis of common plasmids types showed the uniqueness in Russian/Asian isolates of B. miyamotoi compared to other isolates. Conclusions: We here describe the genome of a Russian B. miyamotoi clinical isolate, providing a solid basis for future comparative genomics of B. miyamotoi isolates. This will be a great impetus for further basic, molecular and epidemiological research on this emerging tick-borne pathogen.

show abstract

“…Both in the USA and in Europe, it has been reported that Borrelia miyamotoi disease in people causes fever (up to 40°C), pain and dizziness, chills, sweating, nausea, vomiting, increased thirst and muscle and joints pains. [5,6,13,14,15].…”

Section: Introductionmentioning

confidence: 99%

Borrelia miyamotoi DNA in a patient suspected of Lyme borreliosis

Fiecek

Lewandowska

Roguska

et al. 2019

Preprint

View full text Add to dashboard Cite

Background Clinical manifestations in infection caused by B. miyamotoi can mimick highly variable symptoms of Lyme disease. The aim of our studies was to detect DNA of B. miyamotoi spirochetes in clinical materials from patients suspected of neuroborreliosis(retrospectively).Methods Samples of blood serum and cerebrospinal fluid were collected from 133 patients with clinical manifestations of neuroborreliosis. Diagnosis was established by detection of IgM and / or IgG specific antibodies to B. burgdorferi with ELISA in both sera and CSF. Specificity of positive ELISA results in sera were confirmed with Western-blot test. Bacterial DNA from the collected material was extracted, amplified and sequenced.Results Among 133 patients with clinical manifestations of neuroborreliosis recognized in the years 2010-2018., DNA of B. miyamotoi was detected in CSF from 1 (0.8%) patient with extraocular optic neuritis of the left eye (GenBank accession No. MK674170 and MK674171).Conclusion Detection of B. miyamotoi in patients with central nervous system infections, will allow a better understanding of the epidemiology of infections caused by Borrelia sp. spirochetes. Patients with neurological symptoms and questionable serological findings are a serious diagnostic problem, due to failure to meet the criteria for neuroboreliosis. This indicates the need for further studies of patients with signs of CNS infection.

show abstract

Clinical presentation of Ixodes tick-borne borreliosis caused by Borrelia miyamotoi in the context of an immune response to the pathogen

Abstract: ITBB-BM is a moderate systemic disease accompanied by the production of specific antibodies in virtually all patients.

Cited by 12 publications

References 18 publications

Borrelia miyamotoi infection leads to cross-reactive antibodies to the C6 peptide in mice and men

Borrelia miyamotoi infection leads to cross-reactive antibodies to the C6 peptide in mice and men

Whole genome sequencing of Borrelia miyamotoi isolate Izh-4: reference for a complex bacterial genome

Borrelia miyamotoi DNA in a patient suspected of Lyme borreliosis

Contact Info

Product

Resources

About